Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7955069rdf:typepubmed:Citationlld:pubmed
pubmed-article:7955069lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:7955069lifeskim:mentionsumls-concept:C2698297lld:lifeskim
pubmed-article:7955069lifeskim:mentionsumls-concept:C0003069lld:lifeskim
pubmed-article:7955069lifeskim:mentionsumls-concept:C0005682lld:lifeskim
pubmed-article:7955069lifeskim:mentionsumls-concept:C1511660lld:lifeskim
pubmed-article:7955069lifeskim:mentionsumls-concept:C0332197lld:lifeskim
pubmed-article:7955069lifeskim:mentionsumls-concept:C0045906lld:lifeskim
pubmed-article:7955069lifeskim:mentionsumls-concept:C1553631lld:lifeskim
pubmed-article:7955069pubmed:issue10lld:pubmed
pubmed-article:7955069pubmed:dateCreated1994-11-25lld:pubmed
pubmed-article:7955069pubmed:abstractTextEarlier studies have established that the rodent bladder carcinogen o-anisidine (OA) gives negative results in all of the standard rodent genetic toxicity assays. In the present study, a single oral administration of the maximum tolerated dose level (750 mg/kg) of OA to B6C3F1 mice yielded negative results in 32P-post-labelling assays of bladder and liver DNA (24 h after dosing). Likewise, 14C-ring-labelled OA administered orally to B6C3F1 mice gave no evidence of DNA binding 6, 12 or 24 h later. Administration of OA (750 mg/kg) to transgenic lacI- mice (Big Blue) led to a small increase in mutation frequency (MF) in the bladder, but not in the liver. Increased MFs were observed in the bladder following 1, 3 or 10 daily doses with sampling times of 1 or 2 weeks after the final dose. However, statistical significance (P < 0.01) was only reached 2 weeks after either 3 or 10 daily administrations of OA. The positive control chemical (dimethylnitrosamine) gave a positive result (P < 0.01) in the liver, but not the bladder, 7 days after a single administration of 10 mg/kg. The possibility that OA is mutagenic and carcinogenic to the rodent bladder via formation of radical species is suggested.lld:pubmed
pubmed-article:7955069pubmed:languageenglld:pubmed
pubmed-article:7955069pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7955069pubmed:citationSubsetIMlld:pubmed
pubmed-article:7955069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7955069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7955069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7955069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7955069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7955069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7955069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7955069pubmed:statusMEDLINElld:pubmed
pubmed-article:7955069pubmed:monthOctlld:pubmed
pubmed-article:7955069pubmed:issn0143-3334lld:pubmed
pubmed-article:7955069pubmed:authorpubmed-author:RogersB JBJlld:pubmed
pubmed-article:7955069pubmed:authorpubmed-author:ParryJ MJMlld:pubmed
pubmed-article:7955069pubmed:authorpubmed-author:ShortJ MJMlld:pubmed
pubmed-article:7955069pubmed:authorpubmed-author:AshbyJJlld:pubmed
pubmed-article:7955069pubmed:authorpubmed-author:LefevreP APAlld:pubmed
pubmed-article:7955069pubmed:authorpubmed-author:GlickmanB WBWlld:pubmed
pubmed-article:7955069pubmed:authorpubmed-author:MartinE AEAlld:pubmed
pubmed-article:7955069pubmed:authorpubmed-author:ProvostG SGSlld:pubmed
pubmed-article:7955069pubmed:authorpubmed-author:JonesN JNJlld:pubmed
pubmed-article:7955069pubmed:authorpubmed-author:BurnetteKKlld:pubmed
pubmed-article:7955069pubmed:issnTypePrintlld:pubmed
pubmed-article:7955069pubmed:volume15lld:pubmed
pubmed-article:7955069pubmed:ownerNLMlld:pubmed
pubmed-article:7955069pubmed:authorsCompleteNlld:pubmed
pubmed-article:7955069pubmed:pagination2291-6lld:pubmed
pubmed-article:7955069pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:meshHeadingpubmed-meshheading:7955069-...lld:pubmed
pubmed-article:7955069pubmed:year1994lld:pubmed
pubmed-article:7955069pubmed:articleTitleMutagenicity of o-anisidine to the bladder of lacI- transgenic B6C3F1 mice: absence of 14C or 32P bladder DNA adduction.lld:pubmed
pubmed-article:7955069pubmed:affiliationZeneca Central Toxicology Laboratory, Alderley Park, Cheshire, UK.lld:pubmed
pubmed-article:7955069pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7955069pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed